-
Education, Training, & Certifications
-
-
Selected Grants
-
UCB SL0043 A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severly active systemic lupus erythematosus
awarded by UCB Biopharma
2021 - 2024
-
Prospective observational cohort of patients with moderate-to-severe SLE to characterize cross-sectional and longitudinal disease activity, treatment patterns and effectiveness, outcomes and comorbidities, healthcare resource utilization
awarded by AstraZeneca Pharmaceuticals, LP
2018 - 2023
-
Janssen STELARA Lotus
awarded by Janssen Research & Development, LLC
2018 - 2022
-
Lysosome Defects and the Accumulation of Immune Complexes in Human Lupus
awarded by University of North Carolina - Chapel Hill
2021 - 2022
-
A novel approach to measuring and managing chronic pain, fatigue, and depression in systemic lupus erythematosus.
awarded by Pfizer, Inc.
2019 - 2021
-
The Health-Related Quality of Life, Fatigue and Health Utility of Patients with Lupus Nephritis
awarded by GlaxoSmithKline
2021
-
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
awarded by Gilead Sciences, Inc.
2018 - 2019
-
Phase I MAD Study of JNJ-55920839
awarded by Janssen Pharmaceutica, Inc.
2017 - 2019
-
Cross Sectional and Longitudinal Studies of Immune Complexes in SLE
awarded by University of North Carolina - Chapel Hill
2018 - 2019
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
